{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:05:41Z","timestamp":1784930741324,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010717","name":"Institut Bergoni\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032799","name":"Centre Henri Becquerel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104815","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:04:47Z","timestamp":1779084287000},"page":"104815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0492-654X","authenticated-orcid":false,"given":"Marie","family":"Alexandre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Teruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"de la Motte Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-9371","authenticated-orcid":false,"given":"Etienne","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5269-1251","authenticated-orcid":false,"given":"Monica","family":"Arnedos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-9484","authenticated-orcid":false,"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ange","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Berghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-0725","authenticated-orcid":false,"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-0561","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-9627","authenticated-orcid":false,"given":"Thomas","family":"Grinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-061X","authenticated-orcid":false,"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.breast.2026.104815_bib1","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104815_bib2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in Breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104815_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"12","key":"10.1016\/j.breast.2026.104815_bib4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104815_bib5","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104815_bib6","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.breast.2026.104815_bib7","article-title":"Validity of 1% hormonal receptor positivity cutoff by the ASCO\/college of American pathologists guidelines at the Georgia cancer center","volume":"6","author":"Kreidieh","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104815_bib8","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.annonc.2021.08.1988","article-title":"Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort","volume":"32","author":"Schrodi","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.breast.2026.104815_bib9","article-title":"Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study","volume":"40","author":"Acs","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.breast.2026.104815_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-022-00448-4","article-title":"Impact of low versus negative estrogen\/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer","volume":"8","author":"Yoder","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.breast.2026.104815_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100289","article-title":"The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis","volume":"6","author":"Paakkola","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.breast.2026.104815_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41523-025-00729-8","article-title":"Clinico-pathological factors predicting pathological response in early triple-negative breast cancer","volume":"11","author":"Helal","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2026.104815_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2021.02.020","article-title":"Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - an analysis of 2765 patients from neoadjuvant clinical trials","volume":"148","author":"Villegas","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"7","key":"10.1016\/j.breast.2026.104815_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","article-title":"Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry","volume":"30","author":"Iwamoto","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104815_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1634\/theoncologist.2014-0372","article-title":"Defining breast cancer intrinsic subtypes by quantitative receptor expression","volume":"20","author":"Cheang","year":"2015","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.breast.2026.104815_bib16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.breast.2026.104815_bib17","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cncr.26431","article-title":"Impact of low estrogen\/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers","volume":"118","author":"Raghav","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104815_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.clbc.2013.10.019","article-title":"Survival outcomes in breast cancer patients with low estrogen\/progesterone receptor expression","volume":"14","author":"Balduzzi","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2026.104815_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221077082","article-title":"Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database","volume":"14","author":"Carausu","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"19","key":"10.1016\/j.breast.2026.104815_bib20","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1002\/cncr.29572","article-title":"High incidence of germline BRCA mutation in patients with ER low-positive\/PR low-positive\/HER-2 neu negative tumors","volume":"121","author":"Sanford","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.breast.2026.104815_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.breast.2026.104815_bib22","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"16","key":"10.1016\/j.breast.2026.104815_bib23","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO-24-02263","article-title":"Endocrine therapy omission in Estrogen receptor-low (1%-10%) early-stage breast cancer","volume":"43","author":"Choong","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104815_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-021-00252-6","article-title":"Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort","volume":"7","author":"Grinda","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.breast.2026.104815_bib25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2012-0350","article-title":"Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis","volume":"18","author":"Curtit","year":"2013","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.breast.2026.104815_bib26","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1634\/theoncologist.2008-0048","article-title":"Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management","volume":"13","author":"Guarneri","year":"2008","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.breast.2026.104815_bib27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2010.33.5232","article-title":"Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer","volume":"30","author":"Amir","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104815_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41523-023-00543-0","article-title":"Immune landscape of breast tumors with low and intermediate estrogen receptor expression","volume":"9","author":"Voorwerk","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"12","key":"10.1016\/j.breast.2026.104815_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105907","article-title":"PROMENADE: pembrolizumab for early ER-low\/HER2-negative breast cancer, real-world French cohort","volume":"10","author":"Cherifi","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.breast.2026.104815_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13058-025-02179-3","article-title":"Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study","volume":"27","author":"Steen","year":"2025","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104815_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-025-07628-3","article-title":"Pathologic complete response rates of patients with ER-low\/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study","volume":"211","author":"Bonadio","year":"2025","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:30:22Z","timestamp":1784928622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0960977626001256"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104815","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104815"}}